These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 10822760

  • 1. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C, Steegmann JL, Granda A, de la Cámara R, Figuera A, Arranz R, Gómez-García de Soria V, Alegre A, Fernández-Rañada JM.
    Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
    [Abstract] [Full Text] [Related]

  • 2. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B, Majolino I, Dreger P, Scimè R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N.
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, Yabe H, Kato S, Imoto S, Maruta A, Yoshida T, Gondo H, Morishima Y, Kodera Y.
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [Abstract] [Full Text] [Related]

  • 6. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients.
    Russell LA, Jacobsen N, Heilmann C, Simonsen AC, Christensen LD, Vindelov LL.
    Bone Marrow Transplant; 1996 Aug; 18(2):411-4. PubMed ID: 8864454
    [Abstract] [Full Text] [Related]

  • 7. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
    Choi SJ, Lee JH, Lee JH, Kim S, Lee YS, Seol M, Ryu SG, Lee JS, Kim WK, Jang S, Park CJ, Chi HS, Lee KH.
    Bone Marrow Transplant; 2005 Jul; 36(2):163-9. PubMed ID: 15937507
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML.
    Rahman SL, Mahendra P, Nacheva E, Sinclair P, Arno J, Marcus RE.
    Bone Marrow Transplant; 1998 May; 21(9):955-6. PubMed ID: 9613792
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
    Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, Moreno-Lafont M, García-Latorre E, Ramírez-Sanjuan E, Montiel-Cervantes L, Tripp-Villanueva F, García-León LD, Ayala-Sánchez M, Rosas-Cabral A, Aviña-Zubieta JA, Galindo-Rodríguez G, Vadillo-Buenfil M, Salazar-Exaire D.
    Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
    [Abstract] [Full Text] [Related]

  • 13. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia.
    Gardiner N, Lawler M, O'Riordan JM, Duggan C, De Arce M, McCann SR.
    Bone Marrow Transplant; 1998 Apr; 21(7):711-9. PubMed ID: 9578312
    [Abstract] [Full Text] [Related]

  • 14. [The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes].
    Schattenberg AV, van de Wiel-van Kemenade E, Bär BM, Geurts van Kessel AH, van der Maazen RW, de Witte TJ.
    Ned Tijdschr Geneeskd; 1996 Oct 19; 140(42):2087-91. PubMed ID: 8965951
    [Abstract] [Full Text] [Related]

  • 15. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E, Bandini G, Bonini A, Santucci MA, Martinelli G, Rosti G, Testoni N, Zaccaria A, Tura S.
    Haematologica; 1998 Mar 19; 83(3):231-6. PubMed ID: 9573677
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Ferrá C, Rodríguez-Luaces M, Gallardo D, Encuentra M, Martín-Henao GA, Peris J, Ancín I, Sarrá J, Berlanga JJ, García J, Grañena A.
    Bone Marrow Transplant; 2001 Nov 19; 28(10):963-8. PubMed ID: 11753552
    [Abstract] [Full Text] [Related]

  • 18. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
    Elmaagacli AH, Beelen DW, Trenn G, Schmidt O, Nahler M, Schaefer UW.
    Bone Marrow Transplant; 1999 Apr 19; 23(8):771-7. PubMed ID: 10231138
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.